• Evidence suggests that concurrent therapy for HCV and MDR/RR-TB is feasible, with potential benefits outweighing the hazards.

• Co-administration may improve MDR/RR-TB treatment success while decreasing failures, loss to follow-up, and fatalities.

• These details are provided in the new edition of WHO unified guidelines for the treatment of TB and drug-resistant tuberculosis, with its accompanying Operational Handbook on Tuberculosis: Module 4: therapy. 

• While short-course oral direct-acting antivirals (DAAs) have revolutionized HCV treatment, with over 90% sustained virologic response rates, managing chronic HCV in MDR/RR-TB patients remains a difficulty due to differing national policies.

• This new update further encourages countries to take unified national policies regarding the same.

Click here to read more.